Intended for healthcare professionals

Practice NIHR Alerts

Irritable bowel syndrome: low dose antidepressant improves symptoms

BMJ 2024; 385 doi: (Published 01 May 2024) Cite this as: BMJ 2024;385:q871
  1. Helen Saul, editor in chief1,
  2. Samantha Cassidy, science writer1,
  3. Laura Swaithes, knowledge mobilisation research fellow1,
  4. Alexander C Ford, professor of gastroenterology2
  1. 1NIHR Evidence, Twickenham, UK
  2. 2University of Leeds
  1. Correspondence to H Saul evidence{at}

The study

Ford AC, Wright-Hughes A, Alderson SL, et al. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;402:1773-85.

To read the full NIHR Alert, go to:


  • Competing interests: The BMJ has judged that there are no disqualifying financial ties to commercial companies. Several of the study authors have received funding from charities. See paper for full details.

  • Further details of The BMJ policy on financial interests are here:

  • All authors contributed to the development and review of this summary, as part of the wider NIHR Alerts editorial team.

  • More summaries of NIHR research are available at:

  • Disclaimer: NIHR Alerts are owned by the Department of Health and Social Care and are made available to The BMJ under licence. NIHR Alerts report and comment on health and social care research but do not offer any endorsement of the research. The NIHR assumes no responsibility or liability arising from any error or omission or from the use of any information contained in NIHR Alerts.

  • Permission to reuse these articles should be directed to

View Full Text

Log in

Log in through your institution


* For online subscription